Latest News - Retina

Tuesday, August 15, 2017 | Medical Studies, Retina

UofL Researchers Discover Procedure to Regenerate Dormant Cone Cells, Potentially to Improve Vision in Retinitis Pigmentosa

Researchers at the University of Louisville have discovered a way to revitalize cone receptors that have deteriorated as a result of retinitis pigmentosa (RP). Working with animal models, Henry J. Kap…

Read the full story

Tuesday, August 15, 2017 | Medical Studies, Retina

Real-World Anti-VEGF Results Fall Short in Macular Edema

Real-world patients with diabetic macular edema treated with anti -- vascular endothelial growth factor (VEGF) do not do as well as similar patients in clinical trials, according to an analysis of med…

Read the full story

Monday, August 14, 2017 | Retina, AMD, BioTime

BioTime Announces $2 Million Grant for Further Development of OpRegen for Dry AMD

BioTime has been awarded a new grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2 million) from the Israel Innovation Authority (IIA) to fund the continued development of OpRege…

Read the full story

Monday, August 14, 2017 | Clinical Trials, Retina, AMD, Ophthotech

Ophthotech's Fovista Fails Third Phase 3 Trial in Wet AMD

Ophthotech announced that the prespecified primary endpoint of mean change in visual acuity at 12 months was not achieved in its phase 3 clinical trial investigating the superiority of Fovis…

Read the full story

Wednesday, August 09, 2017 | Clinical Trials, Retina, Allegro Ophthalmics

Allegro Ophthalmics Announces Positive Topline Results From DEL MAR Phase 2B Stage 2 Trial Evaluating Luminate in Patients With DME

Allegro Ophthalmics announced that the DEL MAR Phase 2b Stage 2 clinical trial met its primary endpoint when used as a sequential therapy in patients with diabetic macular edema (DME). The study evalu…

Read the full story

Monday, August 07, 2017 | Medical Studies, Retina

Bariatric Surgery No Guarantee Against Worsening Diabetic Retinopathy

Bariatric surgery does not prevent progression of diabetic retinopathy (DR), according to findings from a new observational study published by Medscape. “All diabetic patients should attend r…

Read the full story

Tuesday, August 01, 2017 | Clinical Trials, Retina, Clearside Biomedical

First Patient Randomized in Clearside's Phase 2 Trial of CLS-TA with Eylea for DME

Clearside Biomedical announced enrollment of the first patient in a phase 2 clinical trial (TYBEE) of CLS-TA for suprachoroidal administration, Clearside’s proprietary suspension formulation of …

Read the full story

Monday, July 31, 2017 | Clinical Trials, Retina, Spark Therapeutics

Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational Luxturna (Voretigene Neparvovec)

Spark Therapeutics announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for Luxturna, the proposed trade name for voretigene nep…

Read the full story

Friday, July 28, 2017 | Retina, AMD

NEI 3-D Retina Organoid Challenge (3-D ROC)

The National Eye Institute (NEI), part of the National Institutes of Health, is seeking ideas for how to develop advances in vitro 3-D human retina organoid models. The goal of the challenge is to tur…

Read the full story

Tuesday, July 25, 2017 | Medical Studies, Retina, Alimera Sciences

New Data Reveal Real-World Benefits of Iluvien Treatment

Latest data from an ongoing audit of real-life UK clinical practice published online in the journal Eye show the number of chronic diabetic macular edema (DME) patients with 6/12 vision, DVLA’s …

Read the full story

Thursday, July 20, 2017 | Retina, Spark Therapeutics

Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational Luxturna (Voretigene Neparvovec) from FDA

Spark Therapeutics announced that the Offices of Orphan Products Development and Pediatric Therapeutics of the FDA have designated investigational Luxturna (voretigene neparvovec) as a drug …

Read the full story

Monday, July 10, 2017 | Retina, Psivida

pSivida Out-Licenses EMEA Rights for Durasert Treatment for Posterior Segment Uveitis While Retaining US Commercial Rights

pSivida announced an amendment of its exclusive license and collaboration agreement with Alimera Sciences that grants Alimera rights to pSivida’s Durasert 3-year treatment for posterior segment …

Read the full story

Friday, June 30, 2017 | Retina, AMD

Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases

NightstaRx announced the completion of a $45 million Series C financing transaction, the proceeds of which will be used for the upcoming phase 3 trial for Nightstar’s lead product candidate, NSR…

Read the full story

Thursday, June 29, 2017 | Medical Studies, Retina, AMD

Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms

Patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of age-related macular degeneration (AMD), according to a Danish registry study. "Blood cancers, which most recent…

Read the full story

Thursday, June 22, 2017 | Retina, Psivida

pSivida Submits Marketing Authorization Application for Approval of Durasert 3-Year Treatment for Posterior Segment Uveitis in the EU

pSivida Corp. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market the company’s Durasert 3-year treatment for posterior s…

Read the full story
Load More